Trial Profile
An open-label study to evaluate the effect of a loading dose followed by a maintenance dose of Bondronat [ibandronic acid] on pain relief in patients with bone pain secondary to metastatic bone disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Feb 2010
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Cancer; Cancer metastases
- Focus Therapeutic Use
- Sponsors Roche
- 16 Apr 2008 Status changed from in progress to completed.
- 24 Apr 2007 New trial record.